In the drug feasibility evaluation, by investigating potential drug development targets for CD5, which exhibits robust associations with CP, a promising candidate for neurological disorder drug development, protein CXCR4, was identified (Fig. 4). The gene discussed is CXCR4; the disease is nervous system disorder.